Literature DB >> 11872362

The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.

Shirya Rashid1, Kristine D Uffelman, Gary F Lewis.   

Abstract

Hypertriglyceridemia and reduced plasma levels of high-density lipoprotein cholesterol (HDL-c) are the most frequent forms of dyslipidemia observed in insulin-resistant states, such as obesity, impaired fasting glucose, and Type 2 diabetes, and are highly atherogenic in these settings. The hypertriglyceridemia of insulin resistance is primarily due to an overproduction of very low-density lipoproteins (VLDL), and in some instances, is also due to reduced VLDL clearance and postprandial accumulation of VLDL, chylomicrons, and their remnants [i.e., triglyceride (TG)-rich lipoproteins]. TG-rich lipoproteins actively exchange their core lipids with HDL in vivo, a process that is facilitated by cholesteryl ester (CE) transfer protein (CETP), and in hypertriglyceridemic states, this process is enhanced. This results in TG enrichment of HDL in hypertriglyceridemic states. There is accumulating evidence that TG enrichment of HDL plays an important role in determining the rate at which HDL particles are cleared from the circulation. Here, we review the evidence that TG-enriched HDL, when modulated by lipolytic enzymes in the circulation, are catabolized more rapidly than native HDL, and may ultimately explain the lowering of HDL-c in insulin-resistant, hypertriglyceridemic states. Since we have recently reviewed in detail the evidence by Lamarche et al. [Clin. Chim. Acta 286 (1999) 145; J. Clin. Invest. 103 (8) (1999) 1191.] to support this hypothesis, in the present brief review, we will focus predominantly on our own recent research in this area.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872362     DOI: 10.1016/s1056-8727(01)00191-x

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  25 in total

1.  Lipase maturation factor 1 is required for endothelial lipase activity.

Authors:  Osnat Ben-Zeev; Maryam Hosseini; Ching-Mei Lai; Nicole Ehrhardt; Howard Wong; Angelo B Cefalù; Davide Noto; Maurizio R Averna; Mark H Doolittle; Miklós Péterfy
Journal:  J Lipid Res       Date:  2011-03-28       Impact factor: 5.922

2.  Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Authors:  Theodosios D Filippatos; Evangelos C Rizos; Vasilios Tsimihodimos; Irene F Gazi; Alexandros D Tselepis; Moses S Elisaf
Journal:  Lipids       Date:  2013-04-02       Impact factor: 1.880

3.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 4.  Risk factors preceding type 2 diabetes and cardiomyopathy.

Authors:  Shamjeet Singh; Sanjiv Dhingra; Dan D Ramdath; Sudesh Vasdev; Vicki Gill; Pawan K Singal
Journal:  J Cardiovasc Transl Res       Date:  2010-07-01       Impact factor: 4.132

5.  Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.

Authors:  Esther M M Ooi; Gerald F Watts; Paul J Nestel; Dmitri Sviridov; Anh Hoang; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

Review 6.  Triglyceride Treatment in the Age of Cholesterol Reduction.

Authors:  Nidhi Agrawal; Patricia Freitas Corradi; Namrata Gumaste; Ira J Goldberg
Journal:  Prog Cardiovasc Dis       Date:  2016-08-17       Impact factor: 8.194

7.  Conjugated linoleic acid reduces hepatic steatosis, improves liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats.

Authors:  Amy Noto; Peter Zahradka; Natalia Yurkova; Xueping Xie; Evan Nitschmann; Malcolm Ogborn; Carla G Taylor
Journal:  Lipids       Date:  2006-02       Impact factor: 1.880

Review 8.  Low-carbohydrate diets, obesity, and metabolic risk factors for cardiovascular disease.

Authors:  Frederick F Samaha; Gary D Foster; Angela P Makris
Journal:  Curr Atheroscler Rep       Date:  2007-12       Impact factor: 5.113

Review 9.  Managing diabetic dyslipidemia: beyond statin therapy.

Authors:  Hemanth Neeli; Ram Gadi; Daniel J Rader
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

Review 10.  Dyslipidemia in type 2 diabetes mellitus.

Authors:  Ramprasad Gadi; Frederick F Samaha
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.